Charles River Laboratories International, Inc.’s Stock Price Takes a Significant Dip at 99.95 USD, Plummeting by 28.13%

Charles River Laboratories International, Inc. (CRL)

99.95 USD -39.12 (-28.13%) Volume: 6.57M

Charles River Laboratories International, Inc.’s stock price currently stands at $99.95, witnessing a substantial drop of -28.13% this trading session, propelled by a robust trading volume of 6.57M. The year-to-date performance also reflects a significant downward trend with a -45.86% change, indicating a challenging market scenario for CRL.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories International Inc. stock has been experiencing fluctuations recently, with underperformance compared to competitors. The company faces potential impacts on its shares as the FDA shifts away from animal testing, leading to a 30% dive in share price. Analysts are closely monitoring the situation, with Barclays adjusting the price target for Charles River ahead of their next earnings report. Despite this, investors are urged to seek counsel due to a securities class action deadline. The FDA’s move towards adopting AI methods and phasing out animal testing requirements has caused further uncertainty in the market, leading to adjustments in price targets by financial institutions. With new developments in the biotech sector, including a new site in Portugal, Charles River Laboratories International Inc. is navigating through a challenging period in the stock market.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Charles River Laboratories International, Inc. shows a mixed long-term outlook. While the company scores moderately in areas such as value and momentum, it receives lower scores in dividend and growth potential. This suggests that investors may find Charles River Laboratories to be a stable investment option with some room for growth, but may not offer significant dividends or rapid expansion in the near future.

Charles River Laboratories International, Inc. is a company that provides essential research tools and support services for drug discovery and development. They cater to a wide range of customers, including pharmaceutical and biotechnology companies, hospitals, and academic institutions. With a focus on providing animal research models for new drugs, devices, and therapies, Charles River Laboratories plays a crucial role in advancing medical research and innovation in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma